The Anti-Infective Innovator Blog

Perspectives on Anti-Infective Drug Development

from Experts in the Trenches 

“Our mission at Spero is to bring novel, life improving therapies to patients suffering from infections, and there are key concepts that are unique to our field and the patients we serve. With the help of our team and key opinion leaders, we aim to amplify these topics for discussion with our collaborators within our field and in the biotech community.”    

     Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics

pattern-bg1

Recent Publications

De-Risking Antibiotic Drug Development with PK-PD

Antibiotic Drug Development:
Asking the Right Questions about Dose Selection Increases Probability of Clinical Success

March 26, 2018
By: Ankit Mahadevia, David Melnick, and Paul Ambrose

A recent analysis of drug development success rates from Phase I to approval found that the average infectious disease drug is 10 times more likely to succeed compared to the average oncology drug (a complementary analysis here–  different magnitude, same directionality).  Why?

-- More Publications Coming Soon --